As other NF-κB-associated targets are also being identified for liver diseases, such as Rho GTPases (Zhang et al., 2018), whether GFL directly acts on the NF-κB pathway, thereby affecting glutamine metabolism, requires further research. This evidence concerns the gene NFKB1 and liver disorder.